We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+24.75%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$562M
AUM Growth
-$50.5M
(-8.3%)
Cap. Flow
-$95.7M
Cap. Flow
% of AUM
-17.03%
Top 10 Holdings %
Top 10 Hldgs %
67.51%
Holding
88
New
30
Increased
9
Reduced
14
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$12.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$6.11M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$5.66M |
| 4 |
OBSV
ObsEva SA Ordinary Shares
OBSV
|
+$5.64M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$22.1M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$15.3M |
| 3 |
Gyre Therapeutics
GYRE
|
+$7.59M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$7.42M |
| 5 |
Arrowhead Research
ARWR
|
+$6.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $112M | 20.01% |
4,750,000
-1,100,000
| -19% | -$22.1M |
|
2
Iovance Biotherapeutics
IOVA
$1.93B
| $51.5M | 9.17% |
4,025,000
-235,000
| -6% | -$3.43M |
|
3
Assembly Biosciences
ASMB
$503M
| $45.6M | 8.11% |
96,833
+3,916
| +4% | +$2.07M |
|
4
argenx
ARGX
$52B
| $37.6M | 6.69% |
453,233
+49,412
| +12% | +$4.42M |
|
|
KDMN
5
DELISTED
Kadmon Holdings, Inc.
KDMN
| $36.1M | 6.44% |
9,060,014
+3,110,014
| +52% | +$12.1M |
|
6
Veracyte
VCYT
$3.58B
| $24.8M | 4.42% |
2,660,210
-657,790
| -20% | -$4.63M |
|
|
CEMI
7
DELISTED
Chembio diagnostics, Inc.
CEMI
| $22.5M | 4.01% |
2,030,533
+23,866
| +1% | +$215K |
|
|
8
Ascendis Pharma A/S
ASND
$16B
| $20.7M | 3.68% |
311,111
-232,889
| -43% | -$15.3M |
|
|
9
Arrowhead Research
ARWR
$12.1B
| $14M | 2.49% |
1,030,330
-731,876
| -42% | -$6.84M |
|
10
IRIDEX
IRIX
$14.4M
| $13.9M | 2.48% |
2,000,000
| – | – |
|
11
Indaptus Therapeutics
INDP
$175M
| $13M | 2.32% |
1,323
+107
| +9% | +$1.19M |
|
|
VRAY
12
DELISTED
ViewRay, Inc.
VRAY
| $10.3M | 1.84% |
1,495,000
-357,878
| -19% | -$2.6M |
|
|
CASM
13
DELISTED
CAS Medical Systems, Inc.
CASM
| $10.3M | 1.83% |
5,263,508
+46,510
| +0.9% | +$69.3K |
|
|
14
Madrigal Pharmaceuticals
MDGL
$11.1B
| $9.73M | 1.73% |
+34,803
| New | +$6.11M |
|
|
15
Gyre Therapeutics
GYRE
$681M
| $9.69M | 1.72% |
110,667
-43,296
| -28% | -$7.59M |
|
16
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
| $9.52M | 1.69% |
100,000
-400,000
| -80% | -$36.8M |
|
|
17
Sarepta Therapeutics
SRPT
$1.68B
| $7.93M | 1.41% |
+60,000
| New | +$5.66M |
|
18
Viking Therapeutics
VKTX
$3.8B
| $7.12M | 1.27% |
+750,000
| New | +$4.99M |
|
19
PUT
Regeneron Pharmaceuticals
REGN
$78.2B
| $6.9M | 1.23% |
+20,000
| New | +$6.26M |
|
20
PUT
iShares MSCI Emerging Markets ETF
EEM
$28.9B
| $6.5M | 1.16% |
150,000
+50,000
| +50% | +$2.31M |
|
|
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $6.42M | 1.14% |
+424,300
| New | +$5.64M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.32M | 1.13% |
+160,000
| New | +$5.08M |
|
|
23
CALL
Assembly Biosciences
ASMB
$503M
| $5.78M | 1.03% |
12,292
-625
| -5% | -$330K |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $4.88M | 0.87% |
+110,500
| New | +$4.55M |
|
25
Coherus Oncology
CHRS
$222M
| $4.83M | 0.86% |
+345,000
| New | +$4.94M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q2 2018 Portfolio in Review
As of Q2 2018, Acuta Capital Partners held 88 positions worth $562M, down 8.3% from $612M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Acuta Capital Partners withdrew a net $95.7M in Q2 2018, closing 29 positions and reducing 14 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $7.42M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 61% a quarter earlier.
Against the trend, Acuta Capital Partners opened a new position in Madrigal Pharmaceuticals worth $9.73M.
- Acuta Capital Partners's largest Q2 2018 buy was Madrigal Pharmaceuticals: 34,803 shares worth $9.73M.
- Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $12.1M increase.
- Acuta Capital Partners's biggest Q2 2018 reduction was Immunomedics Inc, cutting an estimated $22.1M.
- Acuta Capital Partners fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $7.42M.
- Acuta Capital Partners's ten largest holdings make up 68% of its $562M portfolio in Q2 2018.
- Acuta Capital Partners opened 30 new positions and closed 29 in Q2 2018.
- Acuta Capital Partners's portfolio value fell 8.3% quarter-over-quarter to $562M.
Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.